Regulatory Pressure: GMP, Data Integrity & DRAP Inspection Expectations

Biopharma and pharmaceutical laboratories in Pakistan operate under continuous regulatory pressure because laboratory data directly supports product quality, patient safety, and market authorization. Inspections by DRAP and other oversight bodies focus less on analytical outcomes and more on how data is generated, controlled, reviewed, and preserved. This page explains what regulators actually expect and why laboratories often experience high inspection risk even when results meet specifications.

Regulators Assess Systems, Not Individuals

During GMP and DRAP inspections, the central question is not:

     “Did this analyst perform the test correctly?”

but rather:

     “Does this laboratory have a controlled system that consistently produces reliable and defensible data?”

Inspectors evaluate laboratories as data-generation systems, looking for structural weaknesses rather than isolated errors.

Data Integrity Is a Core GMP Requirement

Regulatory expectations align with data integrity principles that require data to be:

  • Attributable – every action linked to a responsible individual
  • Legible – readable, permanent, and understandable
  • Contemporaneous – recorded at the time of activity
  • Original – raw data preserved and retrievable
  • Accurate – free from undocumented changes

Paper worksheets, Excel calculations, and disconnected instrument systems frequently fail to meet these principles under inspection scrutiny.

Traceability Across the Full Data Lifecycle

Inspectors expect laboratories to demonstrate:

  • Clear linkage from sample receipt to final approval
  • Traceability between raw data, calculations, and reports
  • Documented review and authorization steps

Any break in this chain—such as missing raw data or unclear approvals is treated as a critical observation, regardless of result correctness.

Method Control, Validation, and Change Management

Regulators closely examine:

  • Method validation and verification records
  • Evidence that methods were appropriate for intended use
  • Documentation of method changes, deviations, and revalidation

Undocumented or poorly controlled method changes are viewed as serious GMP violations.

Instrument Qualification and Fitness-for-Use

DRAP and GMP inspectors verify that:

  • Instruments were properly qualified (IQ/OQ/PQ)
  • Calibration and maintenance were current
  • Data was generated only when instruments were fit for use

If instrument status cannot be confirmed at the time of analysis, the data is considered non-defensible.

Review, Approval, and Accountability

Inspectors assess whether:

Informal reviews, verbal approvals, or undocumented changes are treated as systemic governance failures.

     Results were reviewed by authorized personnel

     QA approvals were documented and justified

     Corrections and reprocessing were transparently recorded

Stability, Validation, and Long-Term Data Retention

Pharma laboratories must retain and retrieve:

Inability to retrieve complete data sets during inspection raises concerns about long-term data governance.

     Stability study data

     Validation and verification records

     Historical batch and development data

Regulatory Pressure Summary

For biopharma and pharmaceutical laboratories in Pakistan, regulatory pressure centers on data integrity, traceability, and controlled governance. Inspectors focus more on process control and documentation discipline than on individual test values. Without structured systems, laboratories remain vulnerable during GMP and DRAP inspections.